Screener
Sarepta Therapeutics, Inc. SRPT Contingent consideration
Contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonrecurringIncomeExpense.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income | $6,207 | $5,254 | $12,567 | $15,444 |
| Accretion of investment discount, net | 955 | 1,887 | 1,597 | 4,125 |
| Interest expense | (21,508) | (5,228) | (43,221) | (9,731) |
| (Loss) gain on strategic investments | (448) | 36,721 | (2,160) | (54,007) |
| Other, net | (246) | (573) | 918 | (902) |
| Total other (expense) income, net | $(15,040) | $38,061 | $(30,299) | $(45,071) |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s contingent consideration?
- Sarepta Therapeutics, Inc. (SRPT) reported contingent consideration of $246K in Q2 2026.
- What does contingent consideration mean?
- Contingent consideration as reported by Sarepta Therapeutics,, Inc. Common Stock.
Ask your AI about Sarepta Therapeutics, Inc.'s contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude